Methylphenidate and venlafaxine attenuate locomotion in spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder, through α2-adrenoceptor activation

Behavioural Pharmacology

Volumn 24, Issue 4, 2013, Pages 328-331

  Umehara, Masato ^a   Ago, Yukio ^a   Kawanai, Takuya ^a   Fujita, Kazumi ^a   Hiramatsu, Naoki ^a   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

2 adrenoceptor; Attention deficit hyperactivity disorder; Methylphenidate; Spontaneously hypertensive rat; Venlafaxine

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE 1 RECEPTOR; IDAZOXAN; METHYLPHENIDATE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; DRUG EFFECT; HYPERACTIVITY; IMPULSIVENESS; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PSYCHOPHARMACOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC AGENTS; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; MALE; METHYLPHENIDATE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS;

EID: 84880582929     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283633648     Document Type: Article

References (14)

1. Arnsten AF (2009). The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 154:I-S43.
2. Arnsten AF, Dudley AG (2005). Methylphenidate improves prefrontal cortical cognitive function through a2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1:2.
3. Bilodeau M, Simon T, Beauchamp MH, Lespérance P, Dubreucq S, Dorée JP, Tourjman SV (2013). Duloxetine in adults with ADHD: a randomized, placebo-controlled pilot study. J Atten Disord (in press).
4. Findling RL, Greenhill LL, McNamara NK, Demeter CA, Kotler LA, O'Riordan MA, et al. (2007). Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17:433-445.
5. Gamo NJ, Wang M, Arnsten AFT (2010). Methylphenidate and atomoxetine enhance prefrontal function through a2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 49:1011-1023.
6. Gronier B (2011). In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors. Eur Neuropsychopharmacol 21:192-204.
7. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010). Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114:259-270.
8. Langen B, Dost R (2011). Comparison of SHR, WKYand Wistar rats in different behavioural animal models: effect of dopamine D1 and alpha2 agonists. Atten Defic Hyperact Disord 3:1-12.
9. Mahmoudi-Gharaei J, Dodangi N, Tehrani-Doost M, Faghihi T (2011). Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study. Hum Psychopharmacol 26:155-160.
10. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M (2005). Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1239-1247.
11. Tamburella A, Micale V, Mazzola C, Salomone S, Drago F (2012). The selective norepinephrine reuptake inhibitor atomoxetine counteracts behavioral impairments in trimethyltin-intoxicated rats. Eur J Pharmacol 683:148-154.
12. Ueno KI, Togashi H, Mori K, Matsumoto M, Ohashi S, Hoshino A, et al. (2002). Behavioural and pharmacological relevance of stroke-prone spontaneously hypertensive rats as an animal model of a developmental disorder. Behav Pharmacol 13:1-13.
13. Umehara M, Ago Y, Fujita K, Hiramatsu N, Takuma K, Matsuda T (2013). Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats. Eur J Pharmacol 702:250-257.
14. Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, Akhondzadeh S (2010). Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, doubleblind comparison trial. Hum Psychopharmacol 25:530-535. Japan